DYRK1B and liposarcoma: To determine the effects of combinations of conventional chemotherapy agent doxorubicin and DYRK1B targeted therapy on the growth of liposarcoma cells, both SW872 and SW982 cells were co-treated with increasing doses of doxorubicin and AZ191 for five days.